Advert - Roche – Case AUTH/3568/10/21

Typographical error regarding dosing within the Gazyvaro leavepiece


Roche voluntarily admitted a typographical dosing error in a Gazyvaro (obinutuzumab) leavepiece for nurses. As the dosing error could have led to patient safety issues, particularly as it related to the first dose of the medicine, Roche was ruled in breach of the following clauses of the 2021 Code:

Clause 2 - Bringing discredit upon, and reducing confidence in, the pharmaceutical industry
Clause 5.1 - Failing to maintain high standards
Clause 6.1 - Including inaccurate and misleading information